← All trials
NCT03790800
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2019
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 2000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of New South WalesLead sponsor
- Sichuan UniversityCollaborator
- University of New South WalesOverall official - principal investigator
- University of New South WalesReponsible party - principal investigator
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.